Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 160

The DOI matches its Crossref record.

In memoriam

&NA; · 2002 · Journal of Hypertension

Abstract

FigureProfessor Lennart Hansson; 1940–2002 The Journal of Hypertension regrets to announce the loss of Prof. Lennart Hansson. His figure and work are suitably remembered in the following pages by some of his closest associates. The Journal of Hypertension has several particular reasons to join in this remembrance. Lennart had been a member of the Editorial Board for many years, and published many papers in our journal: one contribution of his was in the last month issue of the journal and we know other contributions will appear, alas postumously, next year. As author and scientist Lennart was extremely well known by all those who have worked in the field of hypertension in the past thirty years, and all our readers are familiar with his invaluable contributions to the development and progress of antihypertensive therapy. The Journal of Hypertension is the official organ of the International Society of Hypertension and of the European Society of Hypertension, and of both societies Lennart has been an efficient and prestigious President (1984-1986 of the ISH, 1995-1997 of the ESH), and for both societies he has brilliantly organised successful meetings (Göteborg, June 1979 for ISH; Göteborg, June 2000 for ESH). Last, but not least, Lennart was for many years among the closest friends of the editors of the Journal of Hypertension, who had the privilege to work with him in many studies and shared with him responsabilities in the International and European Societies of Hypertension. We personally feel that, with Lennart, a piece of our life has gone, and are sure this feeling will be shared by a large number of our fellow scientists and friends. Lennart Hansson leaves an invaluable legacy to all those active in hypertension research. He was an outspoken supporter of fruitful, though independent, collaboration of scientists and industry. The outstanding results of his work witness the wisdom of this approach. Although he certainly appreciated the specific benefits that each different class of antihypertensive agents may have, his main message was about the role of lowering blood pressure, ‘the lower the better'. The sufferings of his last days may have been alleviated by seeing his message strongly supported in the World Health Report 2002, recently released by the World Health Organisation, which underlines that more than 50 percent of the yearly burden of 12 million deaths from heart disease and strokes can be cut by efforts to reduce major risk factors, including blood pressure lowering drugs. To pay a tribute to Lennart Hansson, the Journal of Hypertension dedicates this issue to his memory. The only way a scientific journal can honour a scientist is to remember him as a scientist. There was something more than a scientist in Lennart, however. All his friends know that, to quote Blaise Pascal, "on s'attendait de voir un auteur et on a trouvé un homme". Our thoughts are with Lennart's lovely wife, Gerd, and his daughters. Alberto Zanchetti, Giuseppe Mancia Lennart Hansson; 1940–2002 For decades, Lennart Hansson was one of the foremost profiles in hypertension research. His clinical, research, teaching, editorial and written output within this field is truly phenomenal. After a short period of cancer disease, he passed away in the morning of November 08, 2002. Lennart Hansson was born in Landskrona in 1940, and attended college in Varberg before he embarked on his medical studies in Göteborg. He started his scientific career in Göteborg at the Sahlgrenska University Hospital by investigating the clinical and therapeutic effects of beta-blockers. By that time the modern therapeutic management of hypertension was just emerging with the introduction of the beta1-selective blockers, metoprolol and atenolol. He spent time with Stevo Julius in Ann Arbor in the early 1970s doing hypertension research and returned to Europe well set to embark on his international hypertension research career. Lennart Hansson had a true organizational talent. He quickly gathered a group of talented young researchers around him in Göteborg, and introduced them into the clinical and scientific settings of hypertension management and research. For almost two decades he stayed in Göteborg where he served at the Departments of Medicine at Sahlgrenska and Östra Hospitals until 1993 when he moved to Uppsala to continue his career in hypertension research at the Department of Geriatrics. At that time it was still uncertain whether antihypertensive treatment was at all beneficial to the elderly, and whether the ACE inhibitors and calcium antagonists favourably influenced cardiovascular morbidity and mortality in hypertensive patients compared to the traditional treatments, i.e. diuretics and beta-blockers. During some extraordinary creative years from the mid-1990s until his death, he headed more major large outcome trials in hypertension than any other researcher. These major projects included STOP-1, STOP-2, HOT, CAPPP, NORDIL and SCOPE, and w

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1097/00004872-200212000-00001

Cites

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cited by

See all 160

Metadata

Authors
&NA;
Venue
Journal of Hypertension
Published
2002-12
Volume
20
Issue
12
Pages
1
ISSN
0263-6352 (ISSN-L)
OpenAlex
W2438752926
Cited by
160
References
0
Type
other
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: In memoriam. https://app.cochat.ai/papers/10.1097/00004872-200212000-00001
The paper
&NA;. (2002). In memoriam. Journal of Hypertension. https://doi.org/10.1097/00004872-200212000-00001

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.